Clinical Trials Directory

Trials / Completed

CompletedNCT00280605

ALF-ONE : ALFuzosin ONcE Daily

Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
200 (planned)
Sponsor
Sanofi · Industry
Sex
Male
Age
Healthy volunteers
Not accepted

Summary

The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

Conditions

Interventions

TypeNameDescription
DRUGAlfuzosin

Timeline

Start date
2005-08-01
Primary completion
2006-02-01
Completion
2006-02-01
First posted
2006-01-23
Last updated
2010-08-31

Source: ClinicalTrials.gov record NCT00280605. Inclusion in this directory is not an endorsement.

ALF-ONE : ALFuzosin ONcE Daily (NCT00280605) · Clinical Trials Directory